Madaus AG Germany
| Държава: | Германия |
| Кратка информация: | ...1980 AGIOLAX launched in the USA (PERDIEM); its manufacture continues in Cologne, Agiolax production expanded. ...1981 Madaus Diagnostic (MD) presents a product range specially devised for diagnostic investigations of urine in urological laboratories. ...1982 Introduction of AGIOCUR (vegetable fibre from Plantago ovata), a bowel remedy of plant origin, and the beta-receptor blocker ENDAK. ...1984 LEGALON SIL introduced for intravenous treatment of death cap fungus poisoning. ...1985 On 1st January Dr. Madaus and Co. is converted into Dr. Madaus GmbH and Co. Introduction of OXALYT-C* for preventing recurrences of calcium oxalate stones, and of PROVENO-GEL containing the active substance of horse chestnut for the treatment of diseases of veins. ...1986 Introduction of ANIFLAZYM*, an enzyme product for the treatment of inflammatory swellings and suppurative lesions. Granting of GMP Certificate for the manufacture and quality control of Agiolax/Agiocur. ...1989 Restructuring of the group of companies. All the shares in the companies of the Madaus group are held by the newly established Madaus family company GbR, which is represented by a management committee. Dr. Madaus GmbH & Co. is converted into Madaus AG. ...1990 LEGALON 140 introduced. Introduction of SPASMO-LYT, an antispasmodic agent for symptomatic treatment of undue frequency of micturition and nocturia. Introduction of ECHINACIN LIPSTICK and ECHINACIN CAPSETTES. Establishment of a sales force for the five new Lands of the federal German Republic. ...1993 Turnover slumps after implementation of the second Health Structure Reform. Workforce reduced from 1200 to 800 by spring 1994. Introduction of AGIOLAX SPECIAL*, AGNOLYT CAPSULES (extract from the fruits of Agnus castus) and PROSTA URGENIN (extract from Serenoa repens). ...1994 Madaus celebrates its 75th birthday. ...1995 Building of the first phase of the new production plant in Troisdorf-Spich is completed in September. ..1996 Foundation stone for the Agiolax production plant is laid in Goa/India on 20th March. Rebuilding of production units in Troisdorf-Spich is completed. Official opening on 26th April. LEKTINOL, a standardised mistletoe extract, is introduced in December. ..1998 Madaus is represented on the world-wide web online from April 1998. In September, the range of Echinacin products is extended with ECHINACIN-SOLUTION. The alcohol-free solution is especially suitable for children. ..1999 In January, the Agiolax production starts in the Indian city of Goa. The Price for Innovation of the city of Cologne is awarded to Madaus AG. On 1st February, St. John's wort containing preparation FUTURAN is launched. It acts against mild temporary depression. A new market-leading company in the field of urology is founded under the name of HOYER-MADAUS. All urology drugs of Schwarz Pharma AG and Madaus AG are marketed by this joint venture. The homoeopathy branch of Madaus has got ist own WWW presentation since 8th July. Reorganisation and strategic repositioning - current headcount: 436 at Madaus Inc., Cologne, Germany. ..2000 Since beginning of September 2000 all Madaus products in Germany are only obtainable through direct wholesaler trade. From 24th trough 26th October 2000 the 1st virtual conference on phytopharmaceuticals was held exclusively as a virtual internet presentation . Topic: supportive cancer therapies. Launch in Germany of the OTC form Legalon 70 Protect Madaus for the prophylaxis of hepatic disease. ..2001 The virtual conferences "Phytotherapy" were continued online on the www focusing on "rational liver therapies" on March 27th and 28th. Madaus acquires all outstanding shares and assumes managerial control over the phytopharmaceutical Hetterich group, Fürth, Bavaria, Germany in July, 2001. The third virtual congress "Supportive cancer therapy II" is sent in the Internet of 22nd to 23rd October. ..2002 At the beginning of 2002 Hal Allergy was acquired. HAL was one of the oldest family-owned companies with a long-standing tradition in European allergology. The main emphasis of HAL has been put on Hyposensibilisation in order to treat allergies. |
| Сайт: | http://www.madaus.de/1980-2002.199.0.html |
Търсене в сайта
Лекарствен справочник
http://sommons.co/out?zoneId=2647810-2647961 Банер II
